Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the Top 10 Stocks Under $10 That Could Triple. On August 21, JMP Securities ...

Cellistic reveals groundbreaking iPSC-based platforms to accelerate off-the-shelf allogeneic cell therapy development and manufacturing.

By utilizing Accelerated Bio’s innovative hTSC platform, this partnership seeks to deliver iPSC derived from the earliest-stage material, creating an optimal foundation for regenerative medicine.

IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting ...

IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

Fate Therapeutics will present clinical and preclinical data on iPSC-derived therapies at EULAR 2025, focusing on systemic lupus erythematosus.

“As demonstrated today, we remain dedicated to continuously investing in the evolution of our Allo-Evasion™ platform to further enable our iPSC candidates to have a more controlled, durable ...